Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 16;17(1):10.
doi: 10.3390/pediatric17010010.

ABCB1 Polymorphism Is Associated with Higher Carbamazepine Clearance in Children

Affiliations

ABCB1 Polymorphism Is Associated with Higher Carbamazepine Clearance in Children

Natasa Djordjevic et al. Pediatr Rep. .

Abstract

The aim of our study was to investigate the role of ABCB1 polymorphism in the pharmacokinetics of carbamazepine (CBZ) in children. The study enrolled 47 Serbian pediatric epileptic patients on CBZ treatment. Genotyping for ABCB1 1236C<T (rs1128503), 2677G<A/T (rs2032582) and 3435C<T (rs1045642) was carried out using the TaqMan method. Steady-state CBZ serum concentrations were available from our previous study, determined by high pressure liquid chromatography (HPLC). The NONMEM software and one-compartment model were used for pharmacokinetic analysis. ABCB1 1236C<T, 2677G<A/T and 3435C<T variations were found at the frequencies of 47.9%, 48.9% and 52.1%, respectively. The equation that described population clearance (CL) was CL (L/h) = 0.175 + 0.0403 × SEX + 0.0332 × ABCB1 + 0.0176 × CYP1A2 + 0.000151 × DD where SEX has a value of 1 if male and 0 if female, ABCB1 has a value of 1 if C-G-C/T-T-T and 0 if any other ABCB1 diplotype, CYP1A2 has a value of 1 if -163A/A and 0 if -163C/C or C/A, and DD is the total CBZ daily dose (mg/day). The presence of the ABCB1 1236T-2677T-3435T haplotype is associated with an increased clearance of CBZ in pediatric epileptic patients.

Keywords: ABCB1; carbamazepine; children; genetic polymorphism; population pharmacokinetics.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Similar articles

References

    1. Eichelbaum M., Ekbom K., Bertilsson L., Ringberger V.A., Rane A. Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. Eur. J. Clin. Pharmacol. 1975;8:337–341. doi: 10.1007/BF00562659. - DOI - PubMed
    1. Rane A., Hojer B., Wilson J.T. Kinetics of carbamazepine and its 10,11-epoxide metabolite in children. Clin. Pharmacol. Ther. 1976;19:276–283. doi: 10.1002/cpt1976193276. - DOI - PubMed
    1. Thorn C.F., Leckband S.G., Kelsoe J., Leeder J.S., Muller D.J., Klein T.E., Altman R.B. PharmGKB summary: Carbamazepine pathway. Pharmacogenet. Genom. 2011;21:906–910. doi: 10.1097/FPC.0b013e328348c6f2. - DOI - PMC - PubMed
    1. Zybina A., Anshakova A., Malinovskaya J., Melnikov P., Baklaushev V., Chekhonin V., Maksimenko O., Titov S., Balabanyan V., Kreuter J., et al. Nanoparticle-based delivery of carbamazepine: A promising approach for the treatment of refractory epilepsy. Int. J. Pharm. 2018;547:10–23. doi: 10.1016/j.ijpharm.2018.05.023. - DOI - PubMed
    1. Yakusheva E.N., Titov D.S. Structure and Function of Multidrug Resistance Protein 1. Biochemistry. 2018;83:907–929. doi: 10.1134/S0006297918080047. - DOI - PubMed

LinkOut - more resources